琥珀酸福伐曲坦
|
|
|
- CAS号:
- 158930-09-7
- 英文名:
- Frovatriptan Succinate
- 英文别名:
- Vml 251;KB-295988;Sb-209509ax;NCGC00183880-01;FrovatriptanSuccinate;Fovatriptan succinate;Frovatriptan succinate anhydrous;(R)-3-(Methylamino)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamide succinate;(3R)-2,3,4,9-Tetrahydro-3-(methylamino)-1H-carbazole-6-carboxamide butanedioate;butanedioic acid,(6R)-6-(methylamino)-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide
- 中文名:
- 琥珀酸福伐曲坦
- 中文别名:
- 琥珀酸夫罗曲坦;琥珀酸福伐曲坦;夫罗曲普坦琥珀酸盐;琥珀酸福伐曲坦 1G;化合物 T21407;琥珀酸福伐曲坦(琥珀酸夫罗曲坦)
- CBNumber:
- CB21019939
- 分子式:
- C18H23N3O5
- 分子量:
- 361.4
- MOL File:
- 158930-09-7.mol
|
|
|
琥珀酸福伐曲坦化学性质
-
储存条件:
-
Store at -20°C
-
|
-
溶解度:
-
DMSO: 72 mg/mL (199.23 mM);Ethanol: Insoluble
-
|
-
水溶解性:
-
Water: 72 mg/mL (199.23 mM)
-
|
琥珀酸福伐曲坦性质、用途与生产工艺
Frovatriptan Succinate (琥珀酸福伐曲坦)是frovatriptan的琥珀酸盐形式。Frovatriptan是一种合成的曲普坦类serotonin (5-HT) receptor激动剂，特别是对5-HT1B/1D受体。
|
5-HT
1B
Receptor
8.2 (pEC
50
)
|
5-HT
1D
Receptor
|
Cerebral vasodilatation and neurogenic inflammation are considered to be prime movers in the pathogenesis of migraine. Activation of 5-HT
1B
reverses cerebral vasodilatation and activation of 5-HT
1D
prevents neurogenic inflammation. Frovatriptan has a high affinity for 5-HT
1B
and 5-HT
1D
receptors and a moderate affinity for the 5-HT
1A
and 5-HT
1F
receptors subtypes. Frovatriptan has a moderate affinity for the 5-HT
7
receptors, an action associated with coronary artery relaxation in the dog.
Oral bioavailability of Frovatriptan is 22%-30% and is not affected by food. Although the maximum concentration in the plasma is achieved in 2-3 hours, 60%-70% of this is achieved in 1 hour. A steady state is achieved in 4-5 days. Plasma protein binding is low at 15%. The most unique feature is the relative terminal long half-life of about 26 hours. Frovatriptan is chiefly metabolized by CYP1A2 and is cleared by the kidney and liver making moderate failure of either organ not a limiting factor in treatment.
Frovatriptan (0.1, 0.2, and 0.3 mg/kg; a single bolus intraduodenal administration) treatment produces an increase in carotid vascular resistance, which is sustained for at least 5 hours in dogs.
琥珀酸福伐曲坦
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2024/01/16 | S5848 | 琥珀酸福伐曲坦
Frovatriptan Succinate | 158930-09-7 | 25mg | 877.11元 |
| 2024/01/16 | S5848 | Frovatriptan Succinate | 158930-09-7 | 1g | 10401.3元 |
158930-09-7, 琥珀酸福伐曲坦 相关搜索:
- 药靶配体
- 化合物 T21407
- 琥珀酸福伐曲坦(琥珀酸夫罗曲坦)
- 琥珀酸福伐曲坦 1G
- 夫罗曲普坦琥珀酸盐
- 琥珀酸夫罗曲坦
- 琥珀酸福伐曲坦
- 158930-09-7
- Frovatriptan succinate anhydrous
- NCGC00183880-01
- KB-295988
- butanedioic acid,(6R)-6-(methylamino)-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide
- (R)-3-(Methylamino)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamide succinate
- Fovatriptan succinate
- Vml 251
- Sb-209509ax
- Butanedioic acid, compd. with (3R)-2,3,4,9-tetrahydro-3-(methylamino)-1H-carbazole-6-carboxamide (1:1)
- 1H-Carbazole-6-carboxamide, 2,3,4,9-tetrahydro-3-(methylamino)-, (R)-, butanedioate (1:1)
- 1H-Carbazole-6-carboxamide, 2,3,4,9-tetrahydro-3-(methylamino)-, (3R)-, butanedioate (1:1)
- (3R)-2,3,4,9-Tetrahydro-3-(methylamino)-1H-carbazole-6-carboxamide butanedioate
- FrovatriptanSuccinate